ITMI951278A0 - Formulazioni di analoghi dell'insulina - Google Patents

Formulazioni di analoghi dell'insulina

Info

Publication number
ITMI951278A0
ITMI951278A0 ITMI951278A ITMI951278A ITMI951278A0 IT MI951278 A0 ITMI951278 A0 IT MI951278A0 IT MI951278 A ITMI951278 A IT MI951278A IT MI951278 A ITMI951278 A IT MI951278A IT MI951278 A0 ITMI951278 A0 IT MI951278A0
Authority
IT
Italy
Prior art keywords
formulations
insulin analogues
analogues
insulin
Prior art date
Application number
ITMI951278A
Other languages
English (en)
Inventor
Diane Lee Bakaysa
David Nettleship Brems
Bruce Hill Frank
Henry Acken Havel
Allen Howard Pekar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITMI951278(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ITMI951278A0 publication Critical patent/ITMI951278A0/it
Publication of ITMI951278A1 publication Critical patent/ITMI951278A1/it
Application granted granted Critical
Publication of IT1276723B1 publication Critical patent/IT1276723B1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
IT95MI001278A 1994-06-16 1995-06-14 Formulazioni di analoghi dell'insulina IT1276723B1 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (3)

Publication Number Publication Date
ITMI951278A0 true ITMI951278A0 (it) 1995-06-14
ITMI951278A1 ITMI951278A1 (it) 1996-12-14
IT1276723B1 IT1276723B1 (it) 1997-11-03

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
IT95MI001278A IT1276723B1 (it) 1994-06-16 1995-06-14 Formulazioni di analoghi dell'insulina

Country Status (39)

Country Link
US (1) US5474978A (it)
JP (2) JP3171541B2 (it)
KR (1) KR100382326B1 (it)
CN (1) CN1105576C (it)
AT (1) AT408720B (it)
BE (1) BE1009408A5 (it)
BR (1) BR9502795A (it)
CA (1) CA2151560C (it)
CH (2) CH689250A5 (it)
CO (1) CO4410203A1 (it)
CZ (1) CZ287484B6 (it)
DE (1) DE19521720B4 (it)
DK (1) DK173015B1 (it)
ES (1) ES2091727B1 (it)
FI (1) FI118207B (it)
FR (2) FR2721214B1 (it)
GB (1) GB2291427B (it)
GR (1) GR1003004B (it)
HK (1) HK1015138A1 (it)
HU (1) HU227240B1 (it)
IE (1) IE68853B1 (it)
IL (1) IL114151A (it)
IT (1) IT1276723B1 (it)
LU (1) LU88626A1 (it)
MY (1) MY115631A (it)
NL (1) NL1000566C2 (it)
NO (1) NO322128B1 (it)
NZ (1) NZ272359A (it)
PE (1) PE19496A1 (it)
PL (1) PL181310B1 (it)
PT (1) PT101722B (it)
RO (1) RO113530B1 (it)
RS (1) RS49577B (it)
RU (1) RU2152399C2 (it)
SE (1) SE509052C2 (it)
SI (1) SI9500200A (it)
TW (1) TW421596B (it)
UA (1) UA26874C2 (it)
ZA (1) ZA954943B (it)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
AU6299596A (en) * 1995-06-30 1997-02-05 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
WO1997048414A1 (en) * 1996-06-20 1997-12-24 Novo Nordisk A/S INSULIN PREPARATIONS CONTAINING NaCl
PE79099A1 (es) * 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
US6268335B1 (en) 1997-10-24 2001-07-31 Eli Lilly And Company Insoluble insulin compositions
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
PT1121145E (pt) * 1998-10-16 2002-09-30 Novo Nordisk As Preparacoes de insulina contendo mentol e destinadas a administracao via pulmonar
ATE218364T1 (de) * 1998-10-16 2002-06-15 Novo Nordisk As Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
EP1131089B1 (en) * 1998-11-18 2004-02-18 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
AU8436401A (en) * 2000-07-31 2002-02-13 Univ Bar Ilan Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
EP2272501B1 (en) 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
CA2528741A1 (en) 2003-06-17 2004-12-23 Sembiosys Genetics Inc. Methods for the production of insulin in plants
EP2085406A1 (en) * 2003-07-25 2009-08-05 ConjuChem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
EP1711220A1 (en) * 2004-01-16 2006-10-18 Biodel, Inc. Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
CN102040536B (zh) 2004-05-06 2013-06-19 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
ES2586423T3 (es) * 2004-05-14 2016-10-14 Emisphere Technologies, Inc. Compuestos de aril cetona y composiciones para administrar principios activos
US20080044481A1 (en) * 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
EP1773878B1 (en) 2004-07-19 2015-03-04 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
HUE048806T2 (hu) * 2004-10-05 2020-08-28 Novo Nordisk As Inzulin kristályos, valamint szolubilizált formáját tartalmazó gyógyászati készítmény
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1862174A1 (en) * 2005-03-02 2007-12-05 Ajinomoto Co., Inc. Inhibitor for insulin polymer formation
ZA200802546B (en) 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
PE20070548A1 (es) 2005-09-19 2007-07-12 Emisphere Tech Inc Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1991575A1 (en) * 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
MX2008013165A (es) 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
JP5526018B2 (ja) * 2007-03-21 2014-06-18 エミスフェアー・テクノロジーズ・インク アリルオキシおよびアルキルオキシ安息香酸送達薬剤
EP2152243A2 (en) * 2007-04-30 2010-02-17 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2009050738A2 (en) 2007-10-16 2009-04-23 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
ES2443817T3 (es) 2007-11-02 2014-02-20 Emisphere Technologies, Inc. Método para tratar la deficiencia de vitamina B12
JP5780958B2 (ja) 2008-07-31 2015-09-16 ケイス、ウエスタン、リザーブ、ユニバーシティ ハロゲン安定化インスリン
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
BR122013025625B1 (pt) 2008-10-17 2021-08-03 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
EA027757B1 (ru) 2009-01-28 2017-08-31 Смартселлз, Инк. Конъюгат для контролируемой доставки инсулина
JP2012516340A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 合成コンジュゲートおよびその使用
US20110293562A1 (en) 2009-02-12 2011-12-01 Proyecto De Biomedicina Cima, S.L. Use of cardiotrophin-1 for the treatment of metabolic diseases
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
MY159565A (en) 2009-11-13 2017-01-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CA2786854A1 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
NZ602032A (en) * 2010-02-24 2014-11-28 Emisphere Tech Inc Oral b12 therapy
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
KR20140009163A (ko) 2010-09-30 2014-01-22 솔베이(소시에떼아노님) 천연유래 에피클로로히드린의 유도체
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
KR101836957B1 (ko) 2011-03-01 2018-03-09 제이디에스 테라퓨틱스, 엘엘씨 당뇨병, 저혈당 및 관련 장애를 치료 및 예방하기 위한 인슐린과 크롬을 포함하는 조성물
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
KR101983982B1 (ko) 2011-08-29 2019-05-30 사노피-아벤티스 도이칠란트 게엠베하 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2771026A4 (en) 2011-10-27 2015-08-05 Univ Case Western Reserve QUICKLY ULTRA-CONCENTRATED INSULIN ANALOG FORMULATIONS
WO2014004278A1 (en) * 2012-06-26 2014-01-03 The Curators Of The University Of Missouri Photocleavable drug conjugates
WO2014015078A1 (en) 2012-07-17 2014-01-23 Michael Weiss O-linked carbohydrate-modified insulin analogues
CA2889552C (fr) 2012-11-13 2023-10-10 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
CA2889165A1 (en) 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
CN104870469A (zh) 2012-12-26 2015-08-26 沃克哈特有限公司 药物组合物
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
EA201992351A1 (ru) 2017-06-01 2020-03-26 Эли Лилли Энд Компани Быстродействующие композиции инсулина
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
EP4049032A1 (en) 2019-10-25 2022-08-31 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
GB2610490A (en) 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
EP4247429A1 (en) 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
ES2130428T3 (es) * 1993-06-21 1999-07-01 Novo Nordisk As Cristales de insulina asp-b28.
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
US5474978A (en) 1995-12-12
UA26874C2 (uk) 1999-12-29
MY115631A (en) 2003-08-30
LU88626A1 (fr) 1996-02-01
SI9500200A (en) 1996-02-29
PT101722A (pt) 1995-12-29
JP3171541B2 (ja) 2001-05-28
IE68853B1 (en) 1996-07-24
CH689250A5 (de) 1999-01-15
NO952357D0 (no) 1995-06-14
HK1015138A1 (en) 1999-10-08
FI952931A0 (fi) 1995-06-14
PT101722B (pt) 1997-02-28
GR950100229A (en) 1996-02-29
RU95110109A (ru) 1997-05-10
NL1000566A1 (nl) 1995-12-18
YU39695A (sh) 1997-08-22
FR2721214B1 (fr) 1997-09-26
KR100382326B1 (ko) 2003-07-07
AU694501B2 (en) 1998-07-23
IT1276723B1 (it) 1997-11-03
AU2168095A (en) 1996-01-04
GR1003004B (el) 1998-11-05
AT408720B (de) 2002-02-25
GB2291427B (en) 1998-09-16
ZA954943B (en) 1997-09-14
FR2721214A1 (fr) 1995-12-22
NO952357L (no) 1995-12-18
HU9501716D0 (en) 1995-08-28
PE19496A1 (es) 1996-06-01
CZ287484B6 (en) 2000-12-13
FI952931A (fi) 1995-12-17
DK173015B1 (da) 1999-11-15
ATA101695A (de) 2001-07-15
CN1122248A (zh) 1996-05-15
CZ154295A3 (en) 1996-02-14
BE1009408A5 (fr) 1997-03-04
SE509052C2 (sv) 1998-11-30
DE19521720A1 (de) 1995-12-21
RS49577B (sr) 2007-04-10
IE950436A1 (en) 1995-12-27
NZ272359A (en) 1996-10-28
CO4410203A1 (es) 1997-01-09
SE9502167D0 (sv) 1995-06-14
DE19521720B4 (de) 2009-09-03
FR2741078B1 (fr) 1998-08-07
NO322128B1 (no) 2006-08-21
FI118207B (fi) 2007-08-31
HU227240B1 (en) 2010-12-28
IL114151A (en) 2000-09-28
KR960000924A (ko) 1996-01-25
IL114151A0 (en) 1995-10-31
ES2091727A1 (es) 1996-11-01
RO113530B1 (ro) 1998-08-28
JPH083067A (ja) 1996-01-09
JP2001199899A (ja) 2001-07-24
CA2151560A1 (en) 1995-12-17
TW421596B (en) 2001-02-11
RU2152399C2 (ru) 2000-07-10
ITMI951278A1 (it) 1996-12-14
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
PL309098A1 (en) 1995-12-27
BR9502795A (pt) 1996-03-12
CH689935A5 (de) 2000-02-15
GB9512038D0 (en) 1995-08-09
CA2151560C (en) 2000-05-09
SE9502167L (sv) 1995-12-17
HUT73186A (en) 1996-06-28
PL181310B1 (pl) 2001-07-31
DK67795A (da) 1995-12-17
CN1105576C (zh) 2003-04-16
NL1000566C2 (nl) 1996-12-03
FR2741078A1 (fr) 1997-05-16

Similar Documents

Publication Publication Date Title
ITMI951278A0 (it) Formulazioni di analoghi dell'insulina
IT1276722B1 (it) Formulazioni di analoghi monomerici dell'insulina
BR9607935A (pt) Formulações de análogos de insulina monoméricos
DK0626863T3 (da) Formuleringer indeholdende hyaluronsyre
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
TR199701051A3 (tr) 2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi
IT1276799B1 (it) Formulazioni di f-silicone
IT1273471B (it) Derivati dell'acido kojico
ITMI931371A1 (it) Procedimento per la preparazione dell'erdosteina
IT244003Y1 (it) Tenuta d'albero
ITMI912019A1 (it) Analoghi dell'irudina e procedimento per la loro preparazione
KR970000226A (ko) S-이부프로펜의 경구용 제형
IT1283144B1 (it) Agenti fotoprotettori contenenti esteri dell'acido p-metossicinnamico
IT225039Z2 (it) Manipolo per sollecitazioni elettrostatiche dell'epidermide
ITMI930453A1 (it) Composizione farmaceutica avente attivita' antiasmatica
IT1264131B1 (it) Derivato dell'acido iodesossicolico
IT1295003B1 (it) Composizioni farmaceutiche per il trattamento dell'herpes simplex
IT1245982B (it) Codificazione dell'insieme di istruzioni di warren
UA1629S (uk) Набір фестонів "веснянка-5"
IT1290353B1 (it) Medicamento per il trattamento dell'alcolismo
ITMI971894A0 (it) Procedimento per la preparazione di un derivato dell'uridina
ITMI921785A0 (it) Procedimento per la sintesi dell'1-4-butandiolo
UA1999S (uk) Етикетка медичного препарату "димексид"
UA2230S (uk) Етикетка медичного препарату "гідроперит"
UA1951S (uk) Етикетка медичного препарату "валідол"

Legal Events

Date Code Title Description
0001 Granted